Boston Scientific Corporation (NYSE: BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to retire following nearly 30 successful years with the ...

VERAXA Biotech’s majority shareholders are Xlife Sciences AG (SIX: XLS), a Swiss-based publicly listed life science incubator fund, the European Molecular Biology Laboratory ("EMBL"), and its ...

CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced it has received its second Breakthrough Device Designation from the U.S.

"The EVSS represents a new paradigm in peripheral interventions," said Christopher Haig, Co-Founder and CEO of Efemoral Medical. "It's easy to deploy, has high radial strength, can be made in longer ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of Dynamic Biopsy technology, today announced ...

ArticlesFeaturing articles of interest.

Climate-controlled field hospitals have emerged as critical innovations in humanitarian response, military operations, and disaster relief efforts. These sophisticated temporary facilities enable ...

The trial evaluates R3 Vascular’s next-generation drug-eluting bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD, which according to the American Heart Association affects more than 200 ...

R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce ...